AI Science Tracker

Dana-Farber Cancer Institute

1 discovery from 2024

Discoveries

Transcriptome-based machine learning reveals an MCL1 dependency in alveolar soft part sarcoma

A support-vector-regression model trained to infer gene dependencies from RNA-sequencing profiles predicted selective MCL1 dependence in alveolar soft part sarcoma (ASPS), distinct from TFE3-translocation renal cell carcinoma. The authors tested the prediction with CRISPR knockout and the MCL1 inhibitor murizatoclax in two ASPS cell lines; the reported viability effects were greater in ASPS than comparator tRCC lines.

Technology: Transcriptome-based support-vector regression model (RBF kernel; 657 highly predictable gene dependencies)

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: direct test
  • Tested: The authors tested the prediction with CRISPR knockout and the MCL1 inhibitor murizatoclax in two ASPS cell lines; the reported viability effects were greater in ASPS than comparator tRCC lines.
  • Still unknown: bioRxiv preprint, not peer reviewed as stated by PMC. Validation was in two ASPS cell lines with CRISPR and inhibitor assays; it does not establish patient benefit or clinical efficacy. The model nominates dependencies and is not a functional screen itself.
  • AI role: The model predicted per-gene dependency scores from tumor/cell-line expression profiles and prioritized selective vulnerabilities. The study then tested MCL1 dependence in ASPS using three distinct sgRNAs and murizatoclax; those experiments, rather than the prediction alone, provide the reported validation.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11527139/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.